Atherosclerosis and HDL Therapy New Virtual Histology Findings

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Implications from PROSPECT and Future Directions Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Providing.
IVUS-VH & Vulnerable Plaque Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon City, S. Korea Jang-Ho Bae, MD., PhD. Heart Center.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
COI Disclosure I have no conflict of interest to disclose I have no conflict of interest to disclose.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.
ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
Global impact of ischemic heart disease World Heart Federation, 2011.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Modern Management of Cholesterol in the High-Risk Patient.
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
Virtual Histology:From Theory to Vulnerable Plaque Detection Shaoliang Chen MD Nanjing First Hospital Nanjing Cardiovascular Hospital.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Assessment of Coronary Plaque Progression in Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,
Intravascular ultrasound (IVUS) in percutaneous coronary interventions – summary of key articles While angiography is routinely used for assessment of.
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Results of the CARAT Study
Disclosure Statement of Financial Interest
It’s Both the Vulnerable Patient and the Vulnerable Plaque
Results from the intermountain heart collaborative study
The American College of Cardiology Presented by Dr. Steven E. Nissen
Elevated Circulating Levels of Inflammatory Markers in
CTA Characterization of Vulnerable Plaque Minneapolis Heart Institute
The Role of Inflammation and Immune Responses
Should we Use OCT in STEMI Patients?
Clinical need for determination of vulnerable plaques
When IVUS? When FFR? Assessing Intermediate Lesions
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
The American Heart Association Presented by Dr. Steven E. Nissen
Clinical Characteristics
HDL cholesterol and cardiovascular risk Epidemiological evidence
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Neil J. Stone et al. JACC 2014;63:
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
A: Epidemiology update
European Heart Association Journal 2007 April
American College of Cardiology Presented by Dr. Stephan Windecker
Type 2 diabetes: Overlap of clinical conditions
Giuseppe Biondi Zoccai, MD
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Bioresorbable Vascular Scaffolds in Cardiac Allograft Vasculopathy: A New Therapeutic Option  Flavio Ribichini, MD, Michele Pighi, MD, Giuseppe Faggian,
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
Contemporary Evidence-Based Guidelines
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Stephen J. Nicholls, MBBS, PhD; E
Correlation between endothelial function and hypertension
DEScover: One-Year Clinical Results
Goals & Guidelines A summary of international guidelines for CHD
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
The American College of Cardiology Presented by Dr. A. Abazid
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment William Insull, Jr, MD Professor of Medicine and Pediatrics,
Presentation transcript:

Atherosclerosis and HDL Therapy New Virtual Histology Findings M. Pauliina Margolis, MD, PhD

Paulina Margolis, MD, PhD Salary: Volcano Therapeutics, Inc.

Virtual Histology Findings IVUS VH and Lipid profile Total cholesterol, LDL, HDL, and TG Identification of angiographically mild lesions with high risk for a clinical event PROSPECT, VIVA, and Park Preventive Imaging and risk profiling Genetics Other known risk factors Summary and conclusions

IVUS VH and Lipid profile Total cholesterol, LDL, HDL, and TG

IVUS VH and Lipid Profile Forrester JS. Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 2002;137:823–833 An increase in serum HDL-C accelerates reverse cholesterol transport, decreasing the NC size potentially stabilizing plaque

Risk factors for sudden coronary death in men (Missel, Mintz, et al, EHJ 2008 The NC/DC ratio was related to both TC/HDL ratio (r = 0.18, P= 0.0008) and low-density lipoprotein cholesterol levels (r = 0.17, P= 0.002); had a negative correlation with HDL-C levels (r = −0.11, P= 0.03); and was higher for smokers [median 1.98 (1.35–3.18)] vs. non-smokers [median 1.70 (1.23–2.53), P= 0.006]. The ratio of NC to calcification detected by VH-IVUS in diseased coronary segments is related to known risk factors for SCD

Identification of angiographically mild lesions with high risk for a clinical event PROSPECT, VIVA, and Park

A Prospective Natural History Study Of Coronary Atherosclerosis Stone GW, Maehara A, Lansky AJ, et. al. "A Prospective Natural History Study Of Coronary Atherosclerosis" N Engl J Med. 2011 Jan 20;364(3):226-35.

Single Center Study confirms PROSPECT data Association Between IVUS Findings and Adverse Outcomes in Patients With Coronary Artery Disease The VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study Patrick A. Calvert al J Am Coll Cardiol Img 2011;4:894–901, 2011 170 patients with stable angina or troponin-positive ACS referred for percutaneous coronary intervention (PCI) were prospectively enrolled and underwent 3-vessel VH-IVUS pre-PCI and also post-PCI in the culprit vessel. 18 MACE occurred in 16 patients (10.6%) over a median follow-up of 1.7 years and 19 lesions resulted in MACE (11.2%, 13 from non-culprit and 6 from culprit lesions). VH-TCFA (HR: 8.16, p 0.007), plaque burden 70% (HR: 7.48, p 0.001), and minimum luminal area 4 mm2 (HR: 2.91, p 0.036) were associated with total MACE. On patient-based analysis, the only factor associated with MACE was 3-vessel non-calcified VH-TCFA (HR: 1.79, p 0.004).

Impact of plaque characteristics analyzed by intravascular ultrasound on long-term clinical outcomes Kim SH Park SJ et al. Impact of plaque characteristics analyzed by intravascular ultrasound On long term clinical outcomes. Am J Cardiol. 2009 May 1:103(9):1221-6. Epub 2009 Mar 4. 183 patients (79 with stable angina pectoris and 104 with acute coronary syndromes) who underwent pre-intervention 3-vessel IVUS and single-vessel stent implantation. The mean follow-up period was 50 +/- 20 months. In the non-target vessels, the long-term critical event-free rate was 8 % lower in patients with vulnerable plaques (88% vs. 96%, p = 0.04). The multiplicity of vulnerable plaques in the non-target vessels was the only independent predictor of long-term critical events.

Genetics Other known risk factors Risk profiling Genetics Other known risk factors

A Higher Peripheral Blood Gene Expression Score is Associated With Larger Plaque Volume and More Vulnerable Plaque Phenotype as Measured by IVUS VH : Results from the ATLANTA Study Josh, Voros et al. Circ. Imagning 2011 Peripheral gene expression score based on quantitative RNA-measurements was prospectively measured in 18 non-diabetic patients and correlated with IVUS VH plaque type analysis In univariate analysis, the score was associated with plaque volume, NC volume, and DC volume Lp-PLA2 and hsCRP also correlated with plaque in univariate analysis but were not additive to gene score in multivariable ANOVA analysis. A gene expression pattern was associated with higher plaque volume and a more vulnerable plaque phenotype as evidenced by more NC and DC on IVUS/VH. This suggests that the composite gene expression score is not only predictive of obstructive coronary artery disease, but also predictive of higher plaque volume and a more vulnerable plaque phenotype.

Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score Marso SP, et al Intra-Vascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: an analysis from a global IVUS registry. EuroIntervention 2009:5:1-00. Among 531 patients, plaque volume of the most diseased 10mm segment increased with increasing FRS (P=0.0006) Patients with higher FRS estimates of CHD risk had a higher proportion of plaque classified as thin cap fibroatheroma compared with patients in the middle or lower risk score categories (P=0,008)

Lesion in Stable and Unstable Patients. Clin Cardiol 2009 May 19. Plaque Characteristics of the Coronary Segment Proximal to the Culprit Lesion in Stable and Unstable Patients Nakamura T et alPlaque Characteristics of the Coronary Segment Proximal to the Culprit Lesion in Stable and Unstable Patients. Clin Cardiol 2009 May 19. ACS patients showed significantly higher ratio of dense calcium and necrotic core plaque compared with SA patients. VH-IVUS-derived thin-cap fibroatheroma (VH-TCFA) was more frequently observed in ACS patients compared with SA patients Among ACS patients, plasma high sensitivity C-reactive protein (hs-CRP) levels were significantly higher in patients with VH-TCFA than in patients without VH-TCFA (p = 0.004).

The Relationship Between Volumetric Plaque Components And Classical Cardiovascular Risk Factors And The Metabolic Syndrome Zheng M, Choi SY, Tahk SJ, et. al. “The Relationship Between Volumetric Plaque Components And Classical Cardiovascular Risk Factors And The Metabolic Syndrome” JACC Cardiovasc Interv. 2011 May;4(5):503-10. "Whole vessel" VH IVUS analysis was performed in 189 vessels of 63 patients. Three-vessel VH IVUS analysis showed that DM and MS patients had a larger plaque-plus-media burden, larger amount of NC, and more frequent IVUS VH derived TCFAs in coronary arterial trees, implying greater plaque vulnerability in DM and MS patients.

The American journal of cardiology 103(9):1210-4, 2009 Impact of Gender and Age on In Vivo Virtual Histology Imaging Plaque Characterization Qian J, et al.Impact of Gender and Age on In Vivo Virtual Histology Imaging Plaque Characterization The American journal of cardiology 103(9):1210-4, 2009 both women and men had an increase in plaque with increasing age; at any age, men had more plaque than women; percentages of dense calcium and necrotic core increased with increasing patient age in both men and women; and gender differences were lowest in the oldest tercile (>68 years).

170 stable and ACS referred for PCI underwent 3-vessel IVUS VH Leukocyte Telomere Length Is Associated With High-Risk Plaques on Virtual Histology Intravascular Ultrasound and Increased Proinflammatory Activity Calvert et al Arterioscler Thromb Vasc Biol. 2011;31:00-00.) Leukocyte telomere length (LTL) is inversely associated with cardiovascular events. Mean LTL in patients with CAD either before MI or with premature MI have been shown to be 0.3 Kb shorter than in controls, corresponding to a biological age of 11 years older. 170 stable and ACS referred for PCI underwent 3-vessel IVUS VH LTL was not associated with plaque volume but was associated with calcified thin-capped fibroatheroma (OR, 1.24; CI, 1.01–1.53; P0.039) and total fibroatheroma numbers (OR, 1.19; CI, 1.02–1.39; P0.027). Shorter LTL is associated with high-risk plaque morphology on IVUS VH but not total 3-vessel plaque burden suggesting that telomere shortening promotes high-risk plaque subtypes by increasing proinflammatory activity.

In Summary and as Basil Lewis and David Halon so elegantly stated – More Progression Toward Regression? Beyond Low- Density Lipoprotein Cholesterol Lowering Although plaques that rupture and cause an acute event are almost always large , specific plaque characteristics may have greater predictive value. Recent evidence from studies using VH-IVUS shows that characteristics of plaque are related to the major risk factors diabetes, hypertension, and serum LDL-C and HDL-C levels , and that the ratio of necrotic core to dense calcium seems to correlate with LDL-C and the total cholesterol/HDL-C ratio. It appears that plaque characteristics by IVUS VH may indeed relate to outcome events. In the PROSPECT trial, the combination of a large non-culprit plaque burden, small luminal area (4 mm2) and large necrotic core without visible cap (combination found in 15% of this acute coronary syndrome population) was associated with an almost 10-fold increase in major adverse cardiovascular events We need more in vivo information if we are to piece together the missing links in the chain between plaque volume and a clinically relevant event. We appear to be at least somewhat on track in our fight to halt and perhaps reverse the pathology and progression of atherosclerotic vascular disease. JACC 55;2743-2744, 2011